The structure of ibuprofen bound to cyclooxygenase-2

Journal of Structural Biology

Volumn 189, Issue 1, 2015, Pages 62-66

  Orlando, Benjamin J ^a   Lucido, Michael J ^a   Malkowski, Michael G ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Crystal structure; Cyclooxygenase; Ibuprofen; Nonsteroidal anti inflammatory drugs; Prostaglandin H2 synthase

Indexed keywords

ARGININE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; IBUPROFEN; TYROSINE;

ANALGESIA; ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CRYSTALLIZATION; DRUG CONFORMATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME INHIBITOR INTERACTION; HYDROGEN BOND; MEMBRANE BINDING; MUTATIONAL ANALYSIS; NONHUMAN; RACEMIC MIXTURE; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; MOUSE; PROTEIN CONFORMATION;

ANIMALS; CRYSTALLIZATION; CYCLOOXYGENASE 2; IBUPROFEN; MICE; MODELS, MOLECULAR; PROTEIN CONFORMATION;

EID: 84919500197     PISSN: 10478477     EISSN: 10958657     Source Type: Journal    
DOI: 10.1016/j.jsb.2014.11.005     Document Type: Article

References (33)

1. Adams P.D., Afonine P.V., Bunkoczi G., Chen V.B., Davis I.W., Echols N., Headd J.J., Hung L.W., Kapral G.J., Grosse-Kunstleve R.W., McCoy A.J., Moriarty N.W., Oeffner R., Read R.J., Richardson D.C., Richardson J.S., Terwilliger T.C., Zwart P.H. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 2010, 66:213-221.
2. Bhattacharyya D.K., Lecomte M., Rieke C.J., Garavito M., Smith W.L. Involvement of arginine 120, glutamate 524, and tyrosine 355 in the binding of arachidonate and 2-phenylpropionic acid inhibitors to the cyclooxygenase active site of ovine prostaglandin endoperoxide H synthase-1. J. Biol. Chem. 1996, 271:2179-2184.
3. Blobaum A.L., Marnett L.J. Structural and functional basis of cyclooxygenase inhibition. J. Med. Chem. 2007, 50:1425-1441.
4. Davis I.W., Leaver-Fay A., Chen V.B., Block J.N., Kapral G.J., Wang X., Murray L.W., Arendall W.B., Snoeyink J., Richardson J.S., Richardson D.C. MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res. 2007, 35:W375-W383.
5. Dong L., Vecchio A.J., Sharma N.P., Jurban B.J., Malkowski M.G., Smith W.L. Human cyclooxygenase-2 is a sequence homodimer that functions as a conformational heterodimer. J. Biol. Chem. 2011, 286:19035-19046.
6. Duggan K.C., Hermanson D.J., Musee J., Prusakiewicz J.J., Scheib J.L., Carter B.D., Banerjee S., Oates J.A., Marnett L.J. (R)-Profens are substrate-selective inhibitors of endocannabinoid oxygenation by COX-2. Nat. Chem. Biol. 2011, 7:803-809.
7. Emsley P., Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 2004, 60:2126-2132.
8. Gierse J.K., Koboldt C.M., Walker M.C., Seibert K., Isakson P.C. Kinetic basis for selective inhibition of cyclo-oxygenases. Biochem. J. 1999, 339(Pt 3):607-614.
9. Koszelak-Rosenblum M., Krol A.C., Simmons D.M., Goulah C.C., Wroblewski L., Malkowski M.G. His-311 and Arg-559 are key residues involved in fatty acid oxygenation in pathogen-inducible oxygenase. J. Biol. Chem. 2008, 283:24962-24971.
10. Kozak K.R., Prusakiewicz J.J., Marnett L.J. Oxidative metabolism of endocannabinoids by COX-2. Curr. Pharm. Des. 2004, 10:659-667.
11. Kurumbail R.G., Stevens A.M., Gierse J.K., McDonald J.J., Stegeman R.A., Pak J.Y., Gildehaus D., Miyashiro J.M., Penning T.D., Seibert K., Isakson P.C., Stallings W.C. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 1996, 384:644-648.
12. Laneuville O., Breuer D.K., Dewitt D.L., Hla T., Funk C.D., Smith W.L. Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. J. Pharmacol. Exp. Ther. 1994, 271:927-934.
13. Laneuville O., Breuer D.K., Xu N., Huang Z.H., Gage D.A., Watson J.T., Lagarde M., DeWitt D.L., Smith W.L. Fatty acid substrate specificities of human prostaglandin-endoperoxide H synthase-1 and -2. Formation of 12-hydroxy-(9Z, 13E/Z, 15Z)- octadecatrienoic acids from alpha-linolenic acid. J. Biol. Chem. 1995, 270:19330-19336.
14. Langer G., Cohen S.X., Lamzin V.S., Perrakis A. Automated macromolecular model building for X-ray crystallography using ARP/wARP version 7. Nat. Protoc. 2008, 3:1171-1179.
15. Laskowski R.A., MacArthur M.W., Moss D.S., Thornton J.M. PROCHECK - a program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 1993, 26:283-291.
16. Mancini J.A., Riendeau D., Falgueyret J.P., Vickers P.J., O'Neill G.P. Arginine 120 of prostaglandin G/H synthase-1 is required for the inhibition by nonsteroidal anti-inflammatory drugs containing a carboxylic acid moiety. J. Biol. Chem. 1995, 270:29372-29377.
17. McCoy A.J., Grosse-Kunstleve R.W., Adams P.D., Winn M.D., Storoni L.C., Read R.J. Phaser crystallographic software. J. Appl. Crystallogr. 2007, 40:658-674.
18. Orlando B.J., McDougle D.R., Lucido M.J., Eng E.T., Graham L.A., Schneider C., Stokes D.L., Das A., Malkowski M.G. Cyclooxygenase-2 catalysis and inhibition in lipid bilayer nanodiscs. Arch. Biochem. Biophys. 2014, 546:33-40.
19. Otwinowski Z., Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997, 276:307-326.
20. Painter J., Merritt E.A. TLSMD web server for the generation of multi-group TLS models. J. Appl. Crystallogr. 2006, 39:109-111.
21. Painter J., Merritt E.A. Optimal description of a protein structure in terms of multiple groups undergoing TLS motion. Acta Crystallogr. D Biol. Crystallogr. 2006, 62:439-450.
22. Prusakiewicz J.J., Duggan K.C., Rouzer C.A., Marnett L.J. Differential sensitivity and mechanism of inhibition of COX-2 oxygenation of arachidonic acid and 2-arachidonoylglycerol by ibuprofen and mefenamic acid. Biochemistry 2009, 48:7353-7355.
23. Selinsky B.S., Gupta K., Sharkey C.T., Loll P.J. Structural analysis of NSAID binding by prostaglandin H2 synthase: time-dependent and time-independent inhibitors elicit identical enzyme conformations. Biochemistry 2001, 40:5172-5180.
24. Smith W.L., Urade Y., Jakobsson P.J. Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis. Chem. Rev. 2011, 111:5821-5865.
25. Smyth E.M., Grosser T., Wang M., Yu Y., FitzGerald G.A. Prostanoids in health and disease. J. Lipid Res. 2009, 50(Suppl):S423-S428.
26. Thuresson E.D. Prostaglandin Endoperoxide H Synthase-1. The functions of cyclooxygenase active site residues in the binding, positioning, and oxygenation of arachidonic acid. J. Biol. Chem. 2000, 276:10347-10357.
27. Vecchio A.J., Malkowski M.G. The structure of NS-398 bound to cyclooxygenase-2. J. Struct. Biol. 2011, 176:254-258.
28. Vecchio A.J., Malkowski M.G. The structural basis of endocannabinoid oxygenation by cyclooxygenase-2. J. Biol. Chem. 2011, 286:20736-20745.
29. Vecchio A.J., Simmons D.M., Malkowski M.G. Structural basis of fatty acid substrate binding to cyclooxygenase-2. J. Biol. Chem. 2010, 285:22152-22163.
30. Vecchio A.J., Orlando B.J., Nandagiri R., Malkowski M.G. Investigating substrate promiscuity in cyclooxygenase-2: the role of Arg-120 and residues lining the hydrophobic groove. J. Biol. Chem. 2012, 287:24619-24630.
31. Winn M.D., Isupov M.N., Murshudov G.N. Use of TLS parameters to model anisotropic displacements in macromolecular refinement. Acta Crystallogr. D Biol. Crystallogr. 2001, 57:122-133.
32. Yuan C., Rieke C.J., Rimon G., Wingerd B.A., Smith W.L. Partnering between monomers of cyclooxygenase-2 homodimers. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:6142-6147.
33. Yuan C., Sidhu R.S., Kuklev D.V., Kado Y., Wada M., Song I., Smith W.L. Cyclooxygenase allosterism, fatty acid-mediated cross-talk between monomers of cyclooxygenase homodimers. J. Biol. Chem. 2009, 284:10046-10055.